Doustna terapia zaburzeń erekcji - porównanie sildenafilu i tadalafilu Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
paź 20, 2026
Słowa kluczowe:
zaburzenia erekcji, terapia, sildenafil, tadalafil
##plugins.themes.bootstrap3.article.main##
Abstrakt
W pracy omówiono mechanizm działania inhibitorów fosfodiesterazy piątej – leków szeroko wykorzystywanych w doustnej terapii zaburzeń erekcji. Podkreślono podstawowe różnice w ich działaniu i odmienności terapeutyczne. Omówienie koncentruje się głównie na dwóch najczęściej stosowanych substancjach czynnych, którymi pozostają sildenafil i tadalafil.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Sapilak, B. J. (2026). Doustna terapia zaburzeń erekcji - porównanie sildenafilu i tadalafilu. Medycyna Faktów , 19(2(71), 231-236. https://doi.org/10.24292/01.MF.0226.13
Numer
Dział
Artykuły
Copyright by Medical Education. All rights reserved.
Bibliografia
1. Gresser U, Gleiter C. Erectile dysfunction: Comparison of efficacy and side effects of the PDE-5 inhibitors Sildenafil, Vardenafil and Tadalafil. Review of the literature. Eur J Med Res. 2002; 7: 435-46.
2. Lim P. Clinical efficacy and safety of Sildenafil citrate (Viagra) in a multi-racial population in Singapore: A retrospective study of 1520 patients. Int J Urol. 2002; 9: 308-15.
3. Rosen RC, Shabsigh R, Kuritzky L et al. The efficacy of tadalafil in improving sexual satisfaction and overall satisfaction in men with mild, moderate, and severe erectile dysfunction: a retrospective pooled analysis of data from randomized, placebo-controlled clinical trials. Curr Med Res Opin. 2005; 21(11): 1701-9. http://doi.org/10.1185/030079905X65538.
4. Rabijewski M. Awanafil w leczeniu zaburzeń wzwodu prącia. Przegl Urol. 2016; 4: 98.
5. Bryniarski L, Klocek M, Rzepecki M et al. Bezpieczeństwo stosowania inhibitorow 5-fosfodiesterazy w leczeniu zaburzeń erekcji u pacjentów z chorobami układu krążenia. Przegl Lek. 2009; 66 (4): 192-7.
6. Kloner RA, Stanek E, Crowe CL et al. Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data. J Sex Med. 2023; 14; 20(1): 38-48. http://doi.org/10.1093/jsxmed/qdac005.
7. Kloner RA. Cardiovascular profile of Tadalafil. Int J Imp Res. 2002; 14(3): 31.
8. Hellstrom WJ, Overstreet JW, Yu A et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol. 2003; 170(3): 887-91. http://doi.org/10.1097/01.ju.0000081053.97792.da.
9. Starowicz ZL. Inhibitory fosfodiesterazy typu 5 – podobieństwa i rożnice. Seksuologia Polska. 2003; 1(2): 79-82.
10. Ma J, Liu Z, Wu J et al. Role of application of tadalafil 5 mg once-daily (≥6 months) in men with erectile dysfunction from six randomized controlled trials. Transl Androl Urol. 2020; 9(3): 1405-14. http://doi.org/10.21037/tau-19-809.
11. Doggrell SA. Comparison of clinical trials with sildenafil, vardenafil, and tadalafil in erectile dysfunction. Expert Opin Pharmacother. 2005; 6(1): 75-84. http://doi.org/10.1517/14656566.6.1.75.
12. Gong B, Ma M, Xie W et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017; 49(10): 1731-40. http://doi.org/10.1007/s11255-017-1644-5.
13. Cieślikowski WA. Tadalafil 5 mg dziennie w monoterapii BPH/LUTS oraz w terapii skojarzonej z finasterydem u mężczyzn z ED. Przegl Urol. 2014; 3(85): 30-34.
14. Junaid K, Subhojit S. Risk of multiple lower and upper urinary tract problems among male older adults with type-2 diabetes: a population-based study. Aging Male. 2023; 26: 1.
15. Salonia A, Capogrosso P, Boeri L et al. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie’s Disease. Eur Urol. 2025; 88(1): 76-102.
16. Wu H-C, Chang C-P, Shu K et al. Tadalafil improves erectile dysfunction in Taiwanese men with ED. 9th Biennial Meeting of the Asia Pacific SSIR, Cebu 2003, Abstract Book 40.
2. Lim P. Clinical efficacy and safety of Sildenafil citrate (Viagra) in a multi-racial population in Singapore: A retrospective study of 1520 patients. Int J Urol. 2002; 9: 308-15.
3. Rosen RC, Shabsigh R, Kuritzky L et al. The efficacy of tadalafil in improving sexual satisfaction and overall satisfaction in men with mild, moderate, and severe erectile dysfunction: a retrospective pooled analysis of data from randomized, placebo-controlled clinical trials. Curr Med Res Opin. 2005; 21(11): 1701-9. http://doi.org/10.1185/030079905X65538.
4. Rabijewski M. Awanafil w leczeniu zaburzeń wzwodu prącia. Przegl Urol. 2016; 4: 98.
5. Bryniarski L, Klocek M, Rzepecki M et al. Bezpieczeństwo stosowania inhibitorow 5-fosfodiesterazy w leczeniu zaburzeń erekcji u pacjentów z chorobami układu krążenia. Przegl Lek. 2009; 66 (4): 192-7.
6. Kloner RA, Stanek E, Crowe CL et al. Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data. J Sex Med. 2023; 14; 20(1): 38-48. http://doi.org/10.1093/jsxmed/qdac005.
7. Kloner RA. Cardiovascular profile of Tadalafil. Int J Imp Res. 2002; 14(3): 31.
8. Hellstrom WJ, Overstreet JW, Yu A et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol. 2003; 170(3): 887-91. http://doi.org/10.1097/01.ju.0000081053.97792.da.
9. Starowicz ZL. Inhibitory fosfodiesterazy typu 5 – podobieństwa i rożnice. Seksuologia Polska. 2003; 1(2): 79-82.
10. Ma J, Liu Z, Wu J et al. Role of application of tadalafil 5 mg once-daily (≥6 months) in men with erectile dysfunction from six randomized controlled trials. Transl Androl Urol. 2020; 9(3): 1405-14. http://doi.org/10.21037/tau-19-809.
11. Doggrell SA. Comparison of clinical trials with sildenafil, vardenafil, and tadalafil in erectile dysfunction. Expert Opin Pharmacother. 2005; 6(1): 75-84. http://doi.org/10.1517/14656566.6.1.75.
12. Gong B, Ma M, Xie W et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017; 49(10): 1731-40. http://doi.org/10.1007/s11255-017-1644-5.
13. Cieślikowski WA. Tadalafil 5 mg dziennie w monoterapii BPH/LUTS oraz w terapii skojarzonej z finasterydem u mężczyzn z ED. Przegl Urol. 2014; 3(85): 30-34.
14. Junaid K, Subhojit S. Risk of multiple lower and upper urinary tract problems among male older adults with type-2 diabetes: a population-based study. Aging Male. 2023; 26: 1.
15. Salonia A, Capogrosso P, Boeri L et al. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie’s Disease. Eur Urol. 2025; 88(1): 76-102.
16. Wu H-C, Chang C-P, Shu K et al. Tadalafil improves erectile dysfunction in Taiwanese men with ED. 9th Biennial Meeting of the Asia Pacific SSIR, Cebu 2003, Abstract Book 40.